Similarly, inhibition of NKG2A, an inhibitory receptor expressed on NK cells and cytotoxic T cells, with the IgG4 mAb monalizumab in combination with durvalumab demonstrated improved response rates in early-stage studies, particularly in PD-L1-positive NSCLC [120]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.